Dillico is pioneering a cutting-edge, continuous RNA manufacturing platform designed to unleash the potential of mRNA therapeutics. Unlike traditional batch-based approaches, our system enables rapid, scalable, and highly flexible RNA synthesis, purification and formulation, empowering developers to transition seamlessly between different RNA therapies and different production scales without compromising efficiency or quality.
At the heart of Dillico’s innovation lies a robust modeling framework that optimizes every stage of the manufacturing process. By leveraging predictive mechanistic models - based on litterature and data generated internally - we considerably reduce process development experiments, and ensure optimized recipes across different RNA products. This modeling-driven approach not only enhances operational efficiency but also enables rapid adaptation to new product requirements, enabling the platform approach without comprimising with purity and production costs.
